CompletedPhase 4

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

United States121 participantsStarted 2021-05-28

Plain-language summary

The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

Who can participate

Age range17 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with the same score on both sides of the face; and
✓. A minimum of 20 inflammatory lesions (papules and pustules) in total with at least 10 on each side; and
✓. No more than 2 nodules (greater than or equal to \[\>=\] 1 cm in diameter) on the face; and
✓. A minimum of 10 atrophic acne scars in total (\>2 mm)
✓. Inflammatory and non-inflammatory lesions; and
✓. Atrophic acne scars (minimum of 4 scars per half-face)

What they're measuring

Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24

Timeframe: Baseline, Week 24

Trial details

NCT IDNCT04856904

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-02-08

Results submitted2024-03-15

View on ClinicalTrials.gov More Acne Vulgaris trials